Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Formative Research

Date Submitted: Jun 20, 2022
Date Accepted: Feb 14, 2023

The final, peer-reviewed published version of this preprint can be found here:

Patient Feedback on a Mobile Medication Adherence App for Buprenorphine and Naloxone: Closed and Open-Ended Survey on Feasibility and Acceptability

Smith C, Keever A, Bowden T, Olson K, Rodin N, McDonell MG, Roll JM, Smoody G, LeBrun J, McPherson SM

Patient Feedback on a Mobile Medication Adherence App for Buprenorphine and Naloxone: Closed and Open-Ended Survey on Feasibility and Acceptability

JMIR Form Res 2023;7:e40437

DOI: 10.2196/40437

PMID: 37074780

PMCID: 10157459

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

Mobile Medication Adherence Platform for Buprenorphine-Naloxone During Treatment of Opioid Use Disorder: Patient Feedback

  • Crystal Smith; 
  • Abigail Keever; 
  • Theresa Bowden; 
  • Katie Olson; 
  • Nicole Rodin; 
  • Michael G. McDonell; 
  • John M. Roll; 
  • Gillian Smoody; 
  • Jeff LeBrun; 
  • Sterling M. McPherson

ABSTRACT

Background:

Opioid use disorders (OUD) impact the health and well-being of millions of Americans. Buprenorphine or buprenorphine/naloxone (BUP/NAL) can reduce opioid overdose deaths, decrease misuse, and improve quality of life. Unfortunately, poor medication adherence is a primary barrier to long-term efficacy of BUP/NAL.

Objective:

The intent of this investigation was to examine qualitative and quantitative patient feedback on a Bluetooth-enabled pill bottle cap and associated mobile application for patients prescribed BUP/NAL for an OUD.

Methods:

A convenience sample at an OUD outpatient clinic were asked about medication adherence, opioid cravings, experience with technology, and their existent support system through a brief, electronic survey. Patients also provided detailed feedback on features being considered for inclusion in a new technology designed to increase medication adherence, such as inclusion of a personal motivational factor, craving and stress tracking, incentives, and virtual coaching.

Results:

Twenty people (n=20) with an OUD who were prescribed BUP/NAL participated. Participants mean age was 34 years, 65% were female, and 80% Caucasian. Participants had the opportunity to select the most useful, second most useful, and least useful features presented; the large majority indicated that motivational reminders would be most useful (42.1%), followed by craving and stress tracking (26.3%) and online support forums (21.1%).

Conclusions:

Incorporating these suggestions for the described pill-bottle technology may encourage the use of the platform, as well as allow technology developers and BUP/NAL providers to modify this tool for different patient populations. Clinical Trial: N/A


 Citation

Please cite as:

Smith C, Keever A, Bowden T, Olson K, Rodin N, McDonell MG, Roll JM, Smoody G, LeBrun J, McPherson SM

Patient Feedback on a Mobile Medication Adherence App for Buprenorphine and Naloxone: Closed and Open-Ended Survey on Feasibility and Acceptability

JMIR Form Res 2023;7:e40437

DOI: 10.2196/40437

PMID: 37074780

PMCID: 10157459

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.